Trials / Completed
CompletedNCT01499290
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 493 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.
Detailed description
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAZ-AVI | Ceftazidime 2000 mg and 500 mg of avibactam |
| DRUG | Metronidazole | 500 mg of Metronidazole |
| DRUG | Meropenem | 1 gram of Meropenem |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2011-12-26
- Last updated
- 2017-09-06
- Results posted
- 2016-03-01
Locations
56 sites across 20 countries: United States, Argentina, Bulgaria, Croatia, Czechia, Hungary, India, Israel, Latvia, Malaysia, Mexico, Netherlands, Peru, Romania, Russia, South Africa, Spain, Taiwan, Thailand, Ukraine
Source: ClinicalTrials.gov record NCT01499290. Inclusion in this directory is not an endorsement.